Back to top
more

Align Technology (ALGN)

(Delayed Data from NSDQ)

$136.52 USD

136.52
7,975,199

+7.51 (5.82%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $137.20 +0.68 (0.50%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (46 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.

Zacks Equity Research

Is Align Technology (ALGN) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Align Technology (ALGN) Loses 34.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Align Technology (ALGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Equity Research

SYK Stock Falls Despite Q2 Earnings & Sales Beat, '25 View Up

by Zacks Equity Research

SYK's second-quarter results reflect strong segmental performance, along with a rise in operating margin.

Zacks Equity Research

BAX Stock Falls Following Q2 Earnings & Sales Miss, '25 EPS View Down

by Zacks Equity Research

Baxter misses on Q2 earnings and sales, trims full-year EPS view, and posts weaker gross margin. Shares slide nearly 9% pre-market.

Zacks Equity Research

DexCom Stock Falls Despite Q2 Earnings Beat & 2025 Sales View Raise

by Zacks Equity Research

DXCM beats on Q2 earnings and raises 2025 sales guidance, but shares dip as margin pressure dampens investor enthusiasm.

Zacks Equity Research

ALGN Stock Falls on Q2 Earnings and Revenue Miss, Margins Down

by Zacks Equity Research

Align Technology tumbles 34.2% after Q2 earnings and revenues miss estimates as Clear Aligner sales drop and margins tighten further.

Zacks Equity Research

Align Technology (ALGN) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

The headline numbers for Align Technology (ALGN) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Align Technology (ALGN) Q2 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Align Technology (ALGN) delivered earnings and revenue surprises of -3.11% and -4.61%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

RVTY Posts Q2 Earnings & Sales Beat, Raises '25 Sales View

by Zacks Equity Research

Revvity's second-quarter results showcase strong growth in its Diagnostics business, along with recovery in Life Sciences segmental sales.

Zacks Equity Research

WST Stock Rises on Q2 Earnings Beat, EPS View Up on Tariff & FX Benefit

by Zacks Equity Research

West Pharmaceutical's second-quarter top line continues to benefit from revenue growth in its Proprietary Products segment.

Zacks Equity Research

Can Robust Invisalign Momentum Drive Align Technology's Q2 Earnings?

by Zacks Equity Research

ALGN is likely to have delivered robust Q2 2025 performance as Invisalign traction and iTero upgrades gained steam across global markets.

Zacks Equity Research

Align Technology (ALGN) Recently Broke Out Above the 200-Day Moving Average

by Zacks Equity Research

When a stock breaks out above the 200-day simple moving average, good things could be on the horizon. How should investors react?

Zacks Equity Research

Align Technology (ALGN) Just Flashed Golden Cross Signal: Do You Buy?

by Zacks Equity Research

Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?

Zacks Equity Research

If You Invested $1000 in Align Technology a Decade Ago, This is How Much It'd Be Worth Now

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Zacks Equity Research

Why Align Technology (ALGN) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

ALGN or SAUHY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ALGN vs. SAUHY: Which Stock Is the Better Value Option?

Zacks Equity Research

GMED Unveils Next-Gen Oscillating System DuraPro: Stock to Gain?

by Zacks Equity Research

Globus Medical debuts DuraPro with Excelsius integration, boosting its Power Portfolio.

Zacks Equity Research

Is it Prudent to Retain Charles River Stock in Your Portfolio Now?

by Zacks Equity Research

CRL sees momentum in drug discovery and safety services, but macro pressures and currency headwinds threaten growth.

Zacks Equity Research

ABT's FreeStyle Libre 3 Plus Now Available in Canada: Stock to Rise?

by Zacks Equity Research

Abbott debuts FreeStyle Libre 3 Plus in Canada, enhancing diabetes care with the world's smallest glucose sensor.

Zacks Equity Research

Is it Worth Adding Boston Scientific Stock to Your Portfolio Now?

by Zacks Equity Research

BSX rides on strong MedSurg growth and strategic acquisitions amid currency headwinds.

Zacks Equity Research

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Alcon Stock Gains Following UNITY VCS' Approval in Canada

by Zacks Equity Research

ALC's UNITY VCS gets Canada's approval, advancing surgical precision with faster, more efficient technology.

Mark Vickery headshot

Top Analyst Reports for T-Mobile, AstraZeneca & Comcast

by Mark Vickery

TMUS, AZN, and CMCSA each face market headwinds, but new analyst reports highlight strengths shaping their outlooks.

Zacks Equity Research

Should You Retain Henry Schein Stock in Your Portfolio Right Now?

by Zacks Equity Research

Investors are optimistic about HSIC, owing to the strong Henry Schein One performance. However, macro headwinds and fierce competition pose challenges.

Zacks Equity Research

COO Stock Declines Despite Strong Core Growth Amid Fertility Woes

by Zacks Equity Research

The Cooper Companies grows margins and premium products, but fertility softness, inventory cuts, and tariffs weigh on the near-term outlook.